导航抗动脉样硬化补充剂的影响,并承认相关的出血风险
Maria-Zinaida Dobre1, Bogdana Virgolici1, Ioana-Cristina Doicin2
1Department of Biochemistry, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
International journal of molecular sciences
|October 29, 2025
概括
像omega-3和抗氧化剂这样的营养保健品显示出心血管方面的好处,但也带有风险. 需要个性化使用和更多的试验来确认心脏健康的安全性和有效性.
科学领域:
- 心血管科学 心血管科学
- 营养学研究 营养学研究
- 综合医学是一个整体的医学.
背景情况:
- 营养药越来越多地探索心血管益处.
- 机制包括降脂,抗血栓和血管保护作用.
- 现有的证据各不相同,需要仔细考虑产品质量和患者因素.
研究的目的:
- 审查各种营养品对心血管的益处.
- 识别与使用相关的潜在风险和局限性.
- 强调需要个性化治疗和进一步的临床研究.
主要方法:
- 关于营养药和心血管健康的研究的文献综述.
- 对作用机制的分析,包括脂质代谢,血栓形成和血管保护.
- 评估潜在的不良影响,药物相互作用和出血风险.
主要成果:
- 欧米茄-3脂肪酸,柏柏林,大和纳托金酶对新陈代谢和血管健康有很大的影响.
- 抗氧化剂 (维生素C,E,白醇,素,CoQ10) 提供血管保护,但可能会影响血液静止和新陈代谢.
- 草药 (银杏,生,人参,黄素) 具有抗炎性质,但抗凝剂可以增加出血风险.
结论:
- 营养药具有潜在的心血管优势,但由于可变的疗效和安全性,需要个性化应用.
- 诸如出血和药物相互作用等风险需要谨慎使用,特别是在抗血栓治疗中.
- 大规模的临床试验至关重要,以确定最终的安全性和有效性,以便在心血管保健中广泛采用.
相关概念视频
Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Peripheral Artery Disease III: Interprofessional Care
236
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
236
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis IV: Nursing Management
192
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
192
